Avidity exon skipping

Avidity Biosciences Announces Positive AOC 1044 Data

Avidity Biosciences, which received early funding from CureDuchenne, announced positive initial data from their EXPLORE44 Trial for individuals with Duchenne amenable to skipping exon 44.  Their experimental exon-skipping agent, AOC […]

Read More

Avidity Biosciences Webinar: EXPLORE44

A Clinical Trial Investigating the Potential for AOC 1044 to Treat Individuals with DMD Mutations Amenable to Exon 44 Skipping Join Cure Duchenne’s webinar as we welcome Kelly DiTrapani and […]

Read More